Targeting EGFR signalling pathway in triple negative breast cancer
<p>Epidermal growth factor receptor (EGFR) is frequently overexpressed in the majority of triple negative breast cancer patients (TNBC). However, the molecular determinants behind their limited response to EGFR-targeted therapies are poorly understood. Here, both the acute and chronic response...
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | Thesis |
| Idioma: | English |
| Publicado em: |
2014
|
| Assuntos: |